Related Experiment Video
Updated: Feb 25, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Direct acting oral anticoagulant: Bench to bedside
1Senior Advisor (Medicine & Cardiology), Command Hospital (Air Force), Bangalore, India.
Abstract:
Vitamin K antagonists are an effective group of oral anticoagulants. However because of genetic variability in their metabolism and multiple food and drug interactions, these drugs have narrow therapeutic window with unpredictable anticoagulant effects requiring constant monitoring. Several newer direct acting oral anticoagulants have been approved for prevention of stroke in patients with nonvalvular atrial fibrillation and treatment or prevention of venous thromboembolism. The direct acting oral anticoagulants include the direct thrombin inhibitor (dabigatran) and the factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban). These have a better safety and efficacy profile compared to Vitamin K antagonists. Some of the limitations of these drugs include increased risk of gastrointestinal bleeding (except apixaban), increased risk for thrombotic complication upon sudden cessation of therapy and inability to monitor the anticoagulation efficacy. Recent availability of the antidote to these drugs has further strengthened their safety profile. In the current review we will discuss these agents with focus on their potential clinical uses and limitations.
Insights
Newer direct-acting oral anticoagulants offer improved safety and efficacy over Vitamin K antagonists for preventing stroke and venous thromboembolism. While they have limitations, antidotes enhance their safety profile.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Hematology
Background:
- Vitamin K antagonists (VKAs) are effective oral anticoagulants but require constant monitoring due to narrow therapeutic windows and interactions.
- Genetic variability and drug/food interactions lead to unpredictable anticoagulant effects with VKAs.
Purpose of the Study:
- To review direct-acting oral anticoagulants (DOACs) for stroke prevention in nonvalvular atrial fibrillation and venous thromboembolism treatment/prevention.
- To compare the clinical uses and limitations of DOACs versus VKAs.
Main Methods:
- Review of current literature on DOACs, including direct thrombin inhibitors and factor Xa inhibitors.
- Analysis of safety and efficacy profiles, clinical applications, and limitations of DOACs.
Main Results:
- DOACs (dabigatran, rivaroxaban, apixaban, edoxaban) demonstrate better safety and efficacy than VKAs.
- DOACs have limitations including gastrointestinal bleeding risk (except apixaban) and thrombotic risk upon cessation, but antidotes improve safety.
Conclusions:
- DOACs represent a significant advancement in oral anticoagulation therapy.
- Understanding the clinical uses and limitations of DOACs is crucial for optimizing patient care.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Therapeutic Index
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

